Troy Ignelzi

About Troy Ignelzi

Troy Ignelzi is an experienced biopharmaceutical finance executive known for his expertise in corporate finance, capital raising, and building operating infrastructure for fast-growing companies. At Abivax, he was appointed as an independent member of the Board of Directors in July 2023. At the time, the company highlighted his experience in late-stage development, commercial preparation, and financing strategy—capabilities that are especially relevant for a listed biotech executing a major strategic plan. He also serves on Abivax’s audit committee. Professionally, Ignelzi currently serves as Chief Financial Officer of Rapport Therapeutics, according to Abivax’s governance materials. Prior to that, he was CFO of Karuna Therapeutics, where he oversaw finance, business support planning for R&D and commercial readiness, and led multiple private and public financings. Abivax also notes that he held similar senior finance roles at Esperion Therapeutics and scPharmaceuticals, where he helped build the financial and operational infrastructure needed to support a public company. His earlier career includes positions in finance, business development, and strategic planning at Pharmalex, scPharmaceuticals, and Insys Therapeutics, as well as sales experience at Eli Lilly & Co. This background gives him a broad view of biotech operations, from commercial execution to capital strategy. Abivax emphasizes his track record in raising capital, developing development strategies, and building high-performing teams to support long-term financial health. He earned a B.S. in Accounting from Ferris State University. He has also served as Chairman of the Board of Vedanta Biosciences and as a director of CinCor Pharma, which was later acquired by AstraZeneca.